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ABSTRACT
Urothelial cell carcinoma (UCC) of the bladder is one of the most common malignancies, causing considerable morbidity and
mortality worldwide. It is unique among the epithelial carcinomas as two distinct pathways to tumourigenesis appear to exist:
low grade, recurring papillary tumours usually contain oncogenic mutations in FGFR3 or HRAS whereas high grade, muscle
invasive tumours with metastatic potential generally have defects in the pathways controlled by the tumour suppressors p53
and retinoblastoma. Over the last two decades, a number of transgenic mouse models of UCC, containing deletions or mutations
of key tumour suppressor genes or oncogenes, have helped us understand the mechanisms behind tumour development. In this
summary, I present my work investigating the role of the WNT signalling cascade in UCC.
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The incidence of urothelial cell carcinoma (UCC) contin-
ues to rise, with significant implications for our healthcare
systems. In the UK, it is the seventh most common cancer,
accounting for 3% of all new cases, with an estimated
10,399 new cases diagnosed in the UK in 2011.1
UCCs are predominantly transitional cell carcinomas
(TCCs), arising from the transitional epithelium that lines
the bladder. Of these, 70–80% of cases are low grade (LG),
papillary, non-invasive tumours that tend to recur in over
30% of patients despite local excision.2 There is contro-
versy regarding whether these papillary tumours progress
to invasive disease, with progression occurring in approxi-
mately 5% of cases.3 However, whether this is a true pro-
gression or development of de novo muscle invasive
tumours remains unclear. Most morbidity and subsequent
mortality secondary to UCC is due to the high grade (HG),
non-papillary, muscle invasive form of the disease (20–30%
of new TCC cases).4 These invasive tumours penetrate
through the muscularis of the bladder and 50% of patients
relapse with tumours that metastasise to distant sites
despite treatment.5 The five-year survival rate for meta-
static bladder cancer is approximately 7%.6
Clinical and pathological studies have found that these
two forms of UCC arise through at least two separate
mechanisms (Fig 1).7,8 Recently, genomic profiling and
expression studies have identified two separate signatures
for different molecular subtypes of UCC that stratify into
LG or HG disease and can independently predict the likeli-
hood of development of metastasis and disease specific
survival.9–11
Multiple transgenic murine models that attempt to reca-
pitulate the different subtypes of UCC have been developed
to better understand the disease process (Table 1).
The role of WNT signalling in urothelial cell
carcinoma
Human urothelial cell carcinoma
The WNT pathway is conserved widely throughout many
species including Caenorhabditis elegans, Drosophila, Xen-
opus and higher order mammals. It was discovered origi-
nally in Drosophila where the gene wingless demonstrated
the ability to influence segment polarity during larval
development.12 The WNT pathway is now known to control
many events during embryonic development and regulates
homeostatic self-renewal in a number of adult tissues. As a
result, mutations in this pathway are associated with the
onset of various cancers, owing to the influence of the
WNT pathway on processes such as proliferation, motility
and cell fate at the cellular level.13
In colorectal cancer, it is now well established that
germline and somatic mutations of the APC gene, a key
component of the WNT pathway, are found in most
cases.14–16 However, regarding UCC, there was still dubiety
surrounding whether the disease was associated with
somatic mutations of members of the WNT signalling path-
way, including adenomatous polyposis coli (APC)17–20 and
b-catenin.21–23 Loss of heterozygosity has been reported at
the APC locus in 6–50% of UCC tumours analysed, with no
APC mutations identified in tumours (n=24) or cell lines
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(n=4).18–20 Subsequently, evidence of missense (13%) and
frameshift (3%) deletions in the APC protein adjacent to
the b-catenin binding sites was reported.24 Interestingly,
the authors were able to demonstrate that either APC
mutations or b-catenin accumulation was associated with
shorter disease free interval and shorter disease specific
survival in multivariate analysis.
Earlier studies have demonstrated an upregulation of b-
catenin by immunohistochemistry.25–29 In addition, CpG
hypermethylation silencing of the region encoding WNT
inhibitory factor 1, an inhibitor of the WNT signalling path-
way, has been reported as a frequent event in UCC.30 In
another study, epigenetic silencing of the four secreted
frizzled receptor proteins, antagonists of the WNT signal-
ling pathway, has been demonstrated as an independent
predictor of invasive bladder cancer.31
Recent sequencing studies demonstrate alteration of
WNT family members in up to 73% of 131 chemotherapy
naive, muscle invasive, HG bladder tumours (Fig 2).32
It has also been demonstrated recently that urothelial
cancer associated 1 ribonucleic acid (which actives WNT
signalling in a WNT6 dependent manner) increases the cis-
platin resistance of bladder cancer cells in vitro.33
Indeed, in our own studies, we have demonstrated that
WNT signalling is activated in approximately a third of clini-
cal UCC samples.34,35 A significant correlation was observed
between activation of the WNT pathway and either phos-
phoinositide 3-kinase (PI3K) or mitogen activated protein
kinase (MAPK) activation. Interestingly, both groups were
mutually exclusive with almost no overlap between the
WNT/PI3K and the WNT/MAPK tumours (p<0.0001), sug-
gesting a different molecular basis for each tumour subtype.
Modelling mutations of the Wnt pathway in
mouse models
Our findings in the human tissue microarray led us to
hypothesise that activation of WNT signalling could lead
to human UCC but that it required activation of an addi-
tional second mitogenic pathway (either PI3K or MAPK),
leading to distinct subsets of WNT driven tumours. Our
investigation of the mechanistic basis of WNT pathway sig-
nalling in UCC prompted us to examine whether dysregu-
lation of this pathway could induce disease in a murine
model.
In the first instance, to activate Wnt signalling, we used
transgenic mice that carry a dominant allele of the b-cate-
nin gene in which exon 3 is flanked by loxP sequences.36
When a urothelial specific Cre recombinase (UPII-Cre) is
added, exon 3 is deleted, stopping b-catenin from being tar-
geted for degradation, allowing accumulation in the uro-
thelial cells and thus activating the Wnt signalling in a
bladder specific manner.37 Overexpression of nuclear b-cat-
enin led to the formation of localised hyperproliferative
lesions in the bladder epithelium by 3 months, which did
not progress to malignancy despite the mice being aged to
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Figure 1 Important genetic defects that characterise the diverse pathways underlying urothelial cell carcinoma (UCC): Low grade,
non-invasive papillary tumours are associated with mutations in either RAS pathway components or FGFR3, which are thought to be
mutually exclusive. High grade, muscle invasive tumours are associated with loss of p53 or retinoblastoma protein function.
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18 months of age.34 Furthermore, the UPII-Cre+b-cateni-
nexon3/+ mice showed a marked upregulation of the phos-
phatase and tensin homolog (Pten) tumour suppressor
protein that appeared to be a direct consequence of activat-
ing WNT signalling in the bladder, suggesting a potential
compensatory mechanism that could prevent progression
to invasive disease.
In order to investigate this potential block to tumouri-
genesis, we interbred the UPII-Cre+b-cateninexon3/+ mice
with mice engineered to activate either the PI3K (Ptenfl/fl)
or MAPK (HrasQ61L) pathways specifically in the urothe-
lium. In both cases, this overcame the block to tumouri-
genesis and induced a non-invasive UCC phenotype in the
murine bladders. The UPII-Cre+b-cateninexon3/+Ptenfl/fl
tumours contained increased activation of the PI3K path-
way and their growth was dependent on mechanistic target
of rapamycin (mTOR) signalling (ie regression occurred
with rapamycin treatment, an inhibitor of mTOR signal-
ling). In direct contrast, the tumours in UPII-Cre+b-cateni-
nexon3/+HrasQ61L mice, although phenotypically similar,
were driven by MAPK signalling, with no activation of the
PI3K pathway (ie regression occurred with mitogen acti-
vated protein kinase kinase inhibition, an inhibitor of
MAPK signalling, but not with rapamycin).34,35
Consequently, we were able to demonstrate that by using
transgenic models of either WNT/PI3K or WNT/MAPK path-
way activation, we can induce non-invasive UCC in vivo,
leading to tumours with differing molecular and treatment
profiles (Fig 3). These tumours mirror their human counter-
parts with respect to pathway activation secondary to muta-
tions associated with human UCC.
Summary and outlook
Despite transgenic models providing researchers with new
insights into the molecular mechanisms in UCC, many limi-
tations remain. First, recapitulating murine metastatic mod-
els of UCC continues to be challenging with a lack of
spontaneous osseous lesions. The reasons for this could be
multiple, including differences in the pelvic venous drainage
of the mouse, our inability to detect small metastasis in
mouse’s skeleton or the fact that the combinations of genetic
defects are insufficient to initiate bone metastasis. In addi-
tion, one should not disregard the relatively short lifespan of
the mouse, which together with the aggressive nature of the
tumours we are engineering may not allow enough time for
metastatic lesions to develop before the animals must be
sacrificed owing to primary tumour burden.
Table 1 At a glance reference of published genetically engineered mouse models of UCC.57 Reproduced from an article published
in Disease Models & Mechanisms
Mutation Promoter Phenotype References
Hras+ (low copy)
Hras+ (high copy)
UPII
UPII
Low grade, non-invasive (long latency)
Low grade, non-invasive (short latency)
Zhang, 200144
Zhang, 200144
Egfr+
Egfr+Hras+
UPII
UPII
Hyperplasia
Hyperplasia
Cheng, 200245
Cheng, 200245
Fgfr3+
Fgfr3+KrasG12D
Fgfr3+b-cateninexon3/+
Fgfr3+Ptenfl/fl
UPII
UPII
UPII
UPII
Hyperplasia
Hyperplasia
Hyperplasia
Hyperplasia
Ahmad, 201146
Ahmad, 201146
Ahmad, 201146
Foth, 201447
Ncstnfl/fl R26rtTA; tetO- Invasive UCC Rampias, 201448
p53fl/fl
p53fl/fl
p53fl/flHras+
p53fl/flPtenfl/fl
UPII
UPKII
UPII
Adeno-Cre
Hyperplasia and dysplasia
No phenotype
High grade, invasive UCC
Invasive, metastatic UCC
Gao, 200449
Ayala de la Peña, 201150
Gao, 200449
Puzio-Kuter, 200951
Ptenfl/fl
Ptenfl/fl
Ptenfl/fl
Ptenfl/fl
Fabp-Cre
Ksp-Cre
Adeno-Cre
UPII
Low grade UCC
UCC of renal pelvis
No phenotype
No phenotype
Yoo, 2006,52 Tsuruta, 200653
Qian, 200954
Puzio-Kuter, 200951
Ahmad, 201134
Rb-/-
Rb-/-Ptenfl/fl
Rb-/-p53fl/fl
UPII
Adeno-Cre
UPII
No phenotype
No phenotype
Invasive UCC after chemical carcinogenesis
He, 200955
Puzio-Kuter, 200951
He, 200955
SV40 T antigen (low copy)
SV40 T antigen (high copy)
SV40 T antigen
UPII
UPII
UPKII
Carcinoma in situ
Invasive, metastatic UCC
Carcinoma in situ
Zhang, 199956
Zhang, 199956
Ayala de la Peña, 201150
b-cateninexon3/+
b-cateninexon3/+Ptenfl/fl
b-cateninexon3/+HrasQ61L
UPII
UPII
UPII
Hyperplasia
Low grade, non-invasive UCC
Low grade, non-invasive UCC
Ahmad, 201134
Ahmad, 201134
Ahmad, 201135
UCC = urothelial cell carcinoma
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Surprisingly, there remains a paucity of preclinical trials
using these mouse models.35,38,39 As we discover additional
biomarkers and ‘driver’ mutations through sequencing
studies of human UCC, one would hope that we can
develop new mouse models based on these findings.
An exciting development in the transgenic field involves
using unbiased somatic mutagenesis to search for these
‘driver’ genes that contribute to the initiation and/or
progression of UCC. These in vivo transposon-based meth-
ods could help us to identify biologically relevant genetic
lesions in tumourigenesis, allowing identification of events
that collaborate and/or synergise with the common muta-
tions found in UCC.40,41
Despite the emergence of clinical biobanks, next-gener-
ation sequencing and other ‘omic’ approaches, the hetero-
geneity and multifocal nature of clinical UCC means that
WNT1
WNT2
WNT2B
WNT3
WNT3A
WNT4
WNT5B
WNT6
WNT7A
WNT7B
WNT8A
WNT8B
WNT9A
WNT9B
WNT10A
WNT10B
WNT11
WNT16
CTNNB1
APC
WNT5A
5%
8%
5%
7%
6%
3%
11%
5%
8%
17%
5%
9%
9%
6%
3%
9%
8%
6%
4%
17%
14%
genetic alteration Amplification Deep Deletion mRNA Downregulation mRNA Upregulation Missense Mutation Truncating Mutation
Figure 2 Mutational profile of 131 individual cases of muscle invasive urothelial cell carcinoma (http://www.cbioportal.org/public-portal/)
MEK inhibitor
≠RAS
≠WNT
≠WNT
ØPTEN
Rapamycin
Urothelial
cell
cancer
Figure 3 Divergent pathways of WNT driven urothelial cell carcinoma: Our work has suggested that WNT activated/Pten inactivated
tumours are non-invasive tumours that fill the bladders of the mice. They are dependent on mechanistic target of rapamycin (mTOR)
signalling, as highlighted by responsiveness to the mTOR inhibitor rapamycin. By contrast, WNT activated/Ras activated tumours are
non-invasive tumours that are dependent on mitogen activated protein kinase signalling, as demonstrated by their responsiveness to MEK
inhibition but not rapamycin treatment.
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only limited numbers of these studies using clinical materi-
als have produced mature data to inform on disease out-
come in bacillus Calmette–Guérin and chemotherapy
resistant disease, with large sample numbers required to
give statistical significance. However, the information
revealed by cancer genome sequencing has also high-
lighted the simplicity of currently available mouse models:
it is no longer enough to compare a mouse model and a
primary human tumour at the level of tissue and cellular
phenotypes. Nevertheless, mouse models of UCC will con-
tinue to provide invaluable information on the biology of
the disease, with the hope that this can be ultimately trans-
lated to earlier diagnosis and therefore better treatment of
patients with UCC.
Given the critical roles of WNT pathway activation in the
pathophysiology of many human diseases including blad-
der cancer, interest in the development of WNT signalling
inhibitors has intensified (reviewed by Kahn, and Anastas
and Moon).42,43 Different components of the WNT pathway
can be targeted, with multiple agents (including small mol-
ecules, peptides and blocking antibodies) currently in clini-
cal trials.
We have demonstrated that the WNT pathway is only
active in a third of bladder cancers so patient stratification
will be essential. Importantly, as with other cancers, inhib-
iting WNT signalling pathways in bladder cancer alone is
unlikely to result in a substantial improvement in disease
progression owing to the coactivation of additional onco-
genic pathways. Studies aimed at identifying the genetic
factors and biomarkers that can predict responses to treat-
ment with WNT pathway modulators (either alone or in
combination with other therapies) will be an important
next step in determining the utility of these potential new
therapies.
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